Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

This study has been completed.
Elan Pharmaceuticals
Information provided by (Responsible Party):
Biogen Identifier:
First received: March 1, 2004
Last updated: June 14, 2016
Last verified: March 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2005
  Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)